McKesson reported QQ1 2025 results with consolidated revenue of $79.3 billion, up 6% year-over-year, and adjusted diluted EPS of $7.88, up 8% vs. prior year. Management raised full-year adjusted EPS guidance to $31.75–$32.55, reflecting confidence in continued performance across core platforms and ongoing optimization initiatives. The quarter showcased a differentiated mix: robust US Pharmaceutical growth driven by specialty and GLP-1 medications, steady progress in international pharma distribution led by Canada, and notable strength in the oncology ecosystem (US Oncology Network, Ontada, SCRI). These positives were tempered by softer Medical-Surgical demand in core primary care channels and near-term headwinds in Prescription Technology Solutions (RxTS) from product-launch delays and service mix shifts. The board-approved capital allocation actions—15% dividend increase to $0.71 and an additional $4 billion in share repurchases—underscore the visibility McKesson sees in its long-term growth trajectory and cash-generative profile. Management reiterated a disciplined investment plan focused on people, sustainable core growth, oncology/biopharma services, and technology-enabled efficiency. The outlook implies 2025 revenue growth of roughly mid-teens for the company, with second-half earnings contributions expected to be meaningfully stronger as on-ramp costs unwind and efficiency improvements mature.